In the context of DUB inhibitors, Yang et al. revealed that USP8 stabilises PD-L1 through deubiquitination, and combining USP8 inhibitor DUB-IN-2 with anti-PD-L1 therapy potently suppresses pancreatic tumour growth, as demonstrated in the subcutaneous model [149]. Here, USP8 is linked to pancreatic neoplasm.